Drugs / MT-2766
last change Jan 2023 re-read 3 minutes ago

MT-2766

Developed for
COVID-19
Investigated by
Medicago · Tanabe Pharma Corporation

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05065619 Oct 2021 → Mar 2022 COVID-19 Medicago Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MT-2766 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05065619 ↗